The Guidelines World Changed After WHI
Twenty-four years after the Women’s Health Initiative sent shockwaves through medicine, the major health authorities have rebuilt menopause treatment guidelines from the ground up. The 2002 WHI results scared millions of women off hormone therapy and left a generation suffering through hot flashes, bone loss, and vaginal atrophy without help. The recovery has been slow but deliberate. Every major guideline body now agrees: for most women under 60 or within 10 years of menopause onset, the benefits of hormone therapy substantially outweigh the risks. But the nuances matter, and the recommendations are not identical across organizations.
This article walks through what ACOG, The Menopause Society (formerly NAMS), NICE, EMAS, IMS, SOGC, and RACGP actually recommend in their latest 2024–2026 updates. Where they agree, where they diverge, and what those differences mean for you when you sit down with your clinician.
ACOG 2024 Clinical Consensus: What Changed
The American College of Obstetricians and Gynecologists published its most comprehensive menopause treatment hormone therapy guidance in May 2024 under the title “Hormone Therapy for Menopause.” The document was formally designated a Clinical Consensus, meaning it reflects the consensus of a multi-specialty expert panel rather than a single committee. ACOG collaborated with 10 organizations including The Menopause Society, the American Society for Reproductive Medicine, and the Society for Maternal-Fetal Medicine to produce the final version.
The headline change was clear: ACOG now recommends menopausal hormone therapy (MHT) as the most effective treatment for bothersome vasomotor symptoms in healthy women under 60 or within 10 years of menopause onset. The old “lowest dose for shortest duration” framework has been replaced with individualized treatment planning. Dr. Stephanie S. Faubion, medical director of The Menopause Society and a lead contributor to the consensus, stated publicly that the document represents “a sea change from the risk-averse messaging of the past two decades.” ACOG also explicitly recommends against routine use of compounded bioidentical hormones, citing lack of FDA oversight and inconsistent potency, and instead favors FDA-approved body-identical and standard hormone products.
On the practical side, ACOG’s 2024 consensus offers clear dosing tables for transdermal estradiol patches (0.025 to 0.1 mg/day), gels, and micronized progesterone (100 to 200 mg daily), giving clinicians concrete numbers rather than vague ranges. The document also dedicates an entire section to shared decision-making, acknowledging that patient preference plays a legitimate role when the evidence supports multiple valid options.
Menopause Treatment Guidelines from The Menopause Society: 2022 and 2024
The North American Menopause Society rebranded to The Menopause Society in 2023, but the 2022 Hormone Therapy Position Statement remains their current comprehensive guidance. This 78-page document, endorsed by more than 20 medical organizations, remains the most detailed single reference for North American clinicians. The 2022 statement established the current framework: MHT is appropriate for symptomatic women with no contraindications, and the benefit-risk profile is favorable when initiated within the “window of opportunity” — under age 60 or within 10 years of menopause.
What changed in 2024 was not the hormone therapy recommendations themselves but the society’s response to misinformation. In June 2024, The Menopause Society published a formal statement directly addressing the proliferation of misleading claims about menopause treatments on social media and in direct-to-consumer marketing. The statement specifically called out exaggerated claims about “bioidentical” hormones, unjustified fear-mongering about standard HT, and the promotion of unregulated supplements as equivalent to evidence-based treatment. Dr. Faubion, who also leads the society’s medical education efforts, noted that “patients are being sold products that have never been tested for safety or efficacy, often at higher prices than FDA-approved alternatives.”
The practical takeaway is that The Menopause Society’s position has not softened — it has clarified. If anything, the society has become more assertive in pushing back against both undertreatment and unscientific alternatives, making it the most aggressive major voice for evidence-based menopause care in North America.
NICE NG23: The November 2024 and April 2026 Updates
The UK’s National Institute for Health and Care Excellence published the original NG23 guideline in November 2015. After years of criticism that the original was too conservative, NICE issued a major revision in November 2024, followed by a further amendment in April 2026 addressing unscheduled vaginal bleeding on HRT.
The November 2024 update was substantial. NICE now recommends that clinicians offer HRT for menopausal symptoms without requiring laboratory confirmation of menopausal status in women over 45. This was a direct response to the problem of women being denied treatment because their FSH levels didn’t meet arbitrary thresholds. The guideline also specifies that body-identical hormone therapy (transdermal estradiol and micronized progesterone) should be the first-line option, not oral conjugated equine estrogens or synthetic progestins. This aligns with UK prescribing trends but represents a formal departure from the original 2015 guidance, which treated all routes as equivalent.
The April 2026 amendment added clarity on what to do when women on systemic HRT present with unscheduled vaginal bleeding. The update aligns NG23 with NICE’s suspected cancer guideline, specifying that any woman over 40 on HRT who experiences new or unusual vaginal bleeding needs prompt investigation including transvaginal ultrasound and endometrial biopsy as indicated. This is a safety-focused amendment that affects the approximately 15 percent of HRT users who experience breakthrough bleeding in the first six months of treatment.
BMS response to the 2024 update was broadly positive. The British Menopause Society welcomed the alignment with body-identical hormones and the removal of laboratory testing barriers, though they noted the absence of specific guidance on testosterone therapy remains a gap.
EMAS and IMS: The European and International Perspectives
The European Menopause and Andropause Society (EMAS) and the International Menopause Society (IMS) produce clinical guides that influence practice across dozens of countries. The IMS 2024 recommendations on menopausal hormone therapy, published in Climacteric, largely mirror the North American positions but include two notable differences. First, IMS is more permissive about use of MHT beyond age 60 in symptomatic women, framing the decision around individual benefit-risk rather than age cutoffs. Second, IMS explicitly endorses the use of testosterone for hypoactive sexual desire disorder in postmenopausal women, something ACOG and NICE have not fully embraced in their primary guidelines.
EMAS published a revised clinical guide in early 2025 emphasizing individualized treatment and dismissing the “one-size-fits-all” approach that dominated the post-WHI era. EMAS specifically highlights transdermal routes for women with metabolic risk factors, obesity, or hypertension, citing the lower VTE risk compared to oral estrogen. The EMAS guide also dedicates significant space to genitourinary syndrome of menopause, recommending low-dose vaginal estrogen as first-line treatment rather than a last resort.
A key point of agreement across all three organizations — NAMS, IMS, and EMAS — is the rejection of routine laboratory testing to confirm menopause in otherwise healthy women over 45 who present with typical symptoms. The three societies co-signed a joint statement in late 2024 reinforcing this position, calling FSH testing “unnecessary and potentially misleading” in this population.
SOGC Canada and RACGP Australia: Differences Worth Knowing
The Society of Obstetricians and Gynaecologists of Canada (SOGC) updated its menopause guideline in 2024 with a distinctive emphasis on equity and access. The SOGC guideline notes that Canadian women in rural and northern communities face disproportionate barriers to menopause care, with wait times for specialist menopause clinics exceeding 12 months in some provinces. The SOGC recommends that primary care providers be equipped to initiate and manage MHT without specialist referral, and includes specific guidance for prescribing in remote settings where follow-up may be infrequent.
The Royal Australian College of General Practitioners (RACGP) published an updated guide to menopause management in 2024 that takes a notably more pragmatic approach. The RACGP guide includes a two-page clinical algorithm designed for 15-minute consultations — a recognition that Australian GPs manage the vast majority of menopause care without specialist input. The Australian guidelines are also more permissive about testosterone prescribing than their US and UK counterparts, reflecting the growing influence of the Australasian Menopause Society’s position on testosterone for low libido.
Neither SOGC nor RACGP endorse routine use of compounded bioidentical hormones, and both emphasize that the “bioidentical” marketing label is misleading since many FDA-approved or PBS-listed hormones are molecularly identical to endogenous hormones.
Where the Guidelines Still Disagree
Despite broad convergence, meaningful disagreements remain. The most significant is the upper age limit for starting systemic MHT. ACOG and NICE recommend against initiating MHT for the first time in women over 60, citing increased absolute risks of stroke and VTE with oral preparations, as discussed in our article on menopause treatment over 60.
IMS and EMAS take a more flexible view, stating that individual risk assessment may justify initiation beyond 60 in selected symptomatic women. This disagreement matters because approximately 20 percent of women over 60 continue to experience moderate to severe hot flashes, and many were never offered treatment when they were younger.
A second disagreement concerns progesterone dosing. NICE and the BMS recommend 200 mg of micronized progesterone for 12 days per month for women with a uterus who are on sequential HRT. ACOG’s 2024 consensus lists 100 mg daily continuous as a valid option. This sounds like a minor difference, but the dosing affects bleeding patterns, mood side effects, and sleep quality. Women who follow UK dosing may experience heavier scheduled bleeds, while those on US continuous dosing may have less bleeding but more breakthrough spotting.
A third area of divergence is testosterone. The Menopause Society’s 2022 statement calls testosterone “the most underused treatment” in women’s health, recommending it for low sexual desire with distress. But neither ACOG’s 2024 consensus nor NICE NG23 include testosterone as a standard recommendation. This means American and British women face significant hurdles accessing testosterone therapy through standard medical channels, while their counterparts in Australia and parts of Europe have a clearer path.
The Window of Opportunity: How Guidelines Frame Timing
Every major guideline now uses the “window of opportunity” framework for timing of MHT initiation. The concept originated from a 2016 reanalysis of WHI data by Dr. Robert Langer and colleagues, which showed that women who started hormone therapy within 10 years of menopause had dramatically lower risks than those who started a decade or more later. The Coronary Artery Calcium sub-study of WHI, published in 2015, showed that women aged 50 to 59 who used estrogen had lower coronary artery calcium scores than placebo users — a protective signal that disappeared in women who started therapy after age 70.
NICE NG23, the 2024 ACOG consensus, The Menopause Society position, IMS, EMAS, and the SOGC guideline all incorporate the window of opportunity as a central organizing principle. The practical message is simple: if you are in perimenopause or early menopause with symptoms that affect your quality of life, guidelines support treatment now, not later. Dr. JoAnn Manson, chief of preventive medicine at Brigham and Women’s Hospital and a lead WHI investigator, told the Endocrine Society in 2025 that “the timing hypothesis has been validated across multiple datasets. The longer we wait, the more the risk-benefit shifts.”
The one caveat all guidelines share: the window applies to symptom management and bone health. Nobody claims that starting MHT in the window prevents heart disease as a primary indication. That nuance gets lost in social media discussions, but every guideline is clear that MHT should not be prescribed solely for chronic disease prevention.
How This Affects Your Doctor’s Office Visit
What these guidelines mean in practice depends on where you live and who you see. A woman in London seeing an NHS GP should be offered body-identical HRT without lab testing, following NICE NG23. A woman in Toronto seeing a family doctor should be offered MHT with dosing tables from the SOGC guideline. A woman in Sydney should find her GP equipped with the RACGP algorithm and possibly more openness to testosterone. But a woman in rural Alabama or a small town in Saskatchewan may see a clinician who stopped updating their knowledge after 2002 and still believes hormone therapy causes breast cancer in every patient.
The gap between guideline recommendations and clinical reality remains enormous. The Menopause Society estimates that fewer than 25 percent of eligible US women with moderate to severe menopausal symptoms receive MHT, and the rate is comparable in the UK despite NICE’s clear recommendations. The 2024 NAMS/Medscape survey of 1,200 clinicians found that 40 percent admitted they were not comfortable managing menopausal hormone therapy, despite the guidelines being clearer than ever. For a broader overview of all menopause treatment options available, start with our complete guide.
Bottom line: Take these guidelines with you to your appointment. Print the relevant sections. Ask your clinician why, if you’re under 60 and symptomatic, they are not offering treatment that every major health authority in the world now recommends. The guidelines are on your side. Use them.